Payment overview · 2025
General Payments
$14.99
1 reported records · 1 companies
Healthcare provider profile · identity verified
Bruce Pehl, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRAND FORKS, ND · NPI 1154815330
Verified facts
What the public records show
CMS Open Payments records show Bruce Pehl, MD received $14.99 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.99 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1155 | 354 |
| Lisinopril | Lisinopril | 647 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 620 | 158 |
| Omeprazole | Omeprazole | 572 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 161 |
| Metoprolol Succinate | Metoprolol Succinate | 521 | 157 |
| Gabapentin | Gabapentin | 466 | 115 |
| Losartan Potassium | Losartan Potassium | 441 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 420 | 93 |
| Potassium Chloride | Potassium Chloride | 409 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 104 |
| Prednisone | Prednisone | 385 | 238 |
| Simvastatin | Simvastatin | 359 | 101 |
| Metformin Hcl | Metformin Hcl | 351 | 107 |
| Furosemide | Furosemide | 344 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 330 | 94 |
| Tramadol Hcl | Tramadol Hcl | 327 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 89 |
| Trazodone Hcl | Trazodone Hcl | 264 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 69 |
| Ozempic | Semaglutide | 254 | 48 |
| Alprazolam | Alprazolam | 248 | 55 |
| Sertraline Hcl | Sertraline Hcl | 243 | 60 |
| Lorazepam | Lorazepam | 237 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 66 |
| Spironolactone | Spironolactone | 209 | 57 |
| Bupropion Xl | Bupropion Hcl | 203 | 45 |
| Eliquis | Apixaban | 195 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 49 |
| Alendronate Sodium | Alendronate Sodium | 165 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 159 | 31 |
| Azithromycin | Azithromycin | 158 | 137 |
| Pregabalin | Pregabalin | 154 | 28 |
| Ezetimibe | Ezetimibe | 145 | 31 |
| Jardiance | Empagliflozin | 139 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 31 |
| Glipizide | Glipizide | 134 | 33 |
| Montelukast Sodium | Montelukast Sodium | 134 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 54 |
| Allopurinol | Allopurinol | 130 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 36 |
| Warfarin Sodium | Warfarin Sodium | 129 | 22 |
| Metformin Hcl Er | Metformin Hcl | 124 | 45 |
| Clonazepam | Clonazepam | 120 | 22 |
| Januvia | Sitagliptin Phosphate | 118 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 34 |
| Buspirone Hcl | Buspirone Hcl | 111 | 35 |
| Meloxicam | Meloxicam | 106 | 29 |
| Atenolol | Atenolol | 98 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 30 |
| Carvedilol | Carvedilol | 96 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 19 |
| Famotidine | Famotidine | 91 | 33 |
| Finasteride | Finasteride | 88 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 30 |
| Glimepiride | Glimepiride | 72 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 13 |
| Valsartan | Valsartan | 56 | 18 |
| Mirtazapine | Mirtazapine | 54 | 17 |
| Propranolol Hcl | Propranolol Hcl | 51 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 13 |
| Celecoxib | Celecoxib | 50 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 12 |
| Xarelto | Rivaroxaban | 50 | 16 |
| Baclofen | Baclofen | 48 | 11 |
| Ibuprofen | Ibuprofen | 48 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Irbesartan | Irbesartan | 47 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 34 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | 13 |
| Ramipril | Ramipril | 43 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 37 |
| Nabumetone | Nabumetone | 42 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | 15 |
| Lovastatin | Lovastatin | 40 | 12 |
| Aripiprazole | Aripiprazole | 39 | 11 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Nystatin | Nystatin | 37 | 23 |
| Temazepam | Temazepam | 37 | 11 |
| Topiramate | Topiramate | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 28 |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 18 |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 14 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Tamoxifen Citrate | Tamoxifen Citrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.99 · 1 records | AstraZeneca Pharmaceuticals LP | FARXIGA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error